James B. Hawkins - 11 Dec 2025 Form 4 Insider Report for IRADIMED CORP (IRMD)

Reporting relationship: Director
Issuer ticker: IRMD
Reported as of: 11 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Dec 2025, 17:00:18 UTC
Prior SEC filing: 10 Dec 2025
Next SEC filing: 16 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ James B. Hawkins

Key filing fact

James B. Hawkins filed Form 4 for IRADIMED CORP (IRMD) on 12 Dec 2025.

Key facts

This page summarizes James B. Hawkins's Form 4 filing for IRADIMED CORP (IRMD).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Dec 2025, 17:00.

Change

Previous filing in this sequence was filed on 10 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0000898243 Primary reporting owner

HAWKINS JAMES B

Relationship: Director
Address: C/O IRADIMED CORPORATION, 12705 INGENUITY DRIVE, ORLANDO
Signature: /s/ James B. Hawkins
Signature date: 12 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IRMD transaction

Common Stock

Options Exercise

Transaction value
Shares: +905
Change %: +3.1%
Price
Shares after: 29,647
Date: 11 Dec 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IRMD transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -905
Change %: -50%
Price: $0.000000
Shares after: 906
Date: 11 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 905
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Restricted stock units convert into common stock on a one-for-one basis.

Footnote F2

On December 11, 2024, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.